The Europe Male Infertility Market is expected to witness market growth of 7.2% CAGR during the forecast period (2020-2026).
Elements of adult and gender identity can never be realized in infertile individuals due to the loss of pregnancy, childbirth, and lack of family and generational continuity and inclusiveness within their wider community. High levels of clinically relevant symptoms of depression and anxiety, suicidal thoughts, and a heavy conceptualization of grief impact infertile individuals. Mental health and psychosocial problems and resources need to address key factors of depression, such as poverty, sexual abuse, and infertility.
Growing rates of infertility worldwide and the introduction of assisted reproductive technologies (ARTs) are expected to push the demand for male infertility in the coming years. ARTs address a wide variety of infertility therapies that provide remedies for males facing issues such as reduced sperm count, irregular sperm quality, and poor motility. In addition, ARTs deliver a high success rate compared to drugs. The demand for male infertility is expected to see substantial development in the future due to technical developments in the area of assisted reproductive technology.
Increased demand for Assisted Reproductive Technologies [ART] is the most important reason for increasing income for male infertility worldwide. Assisted Reproductive Technologies [ART] assists males suffering from low sperm counts, sperm with reduced motility, or no sperm counts. In addition, a higher percentage of achievements related to medicine and improvement in expertise is expected to raise demand in the immediate future. It stimulates the growth of the market.
Based on Treatment, the market is segmented into Assisted Reproductive Technology & Varicocele Surgery and Medication. Based on Test, the market is segmented into DNA Fragmentation Technique, Oxidative Stress Analysis, Computer Assisted Semen Analysis, Microscopic Examination, Sperm Agglutination, Sperm Penetration Assay and Other Tests. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Sanofi S.A., Bayer AG, Cadila Healthcare Ltd. (Zydus Cadila), Endo International PLC, Aytu BioScience, Inc., Vitrolife AB, SCSA Diagnostics, Inc., Andrology Solutions Limited, Halotech DNA SL, and Intas Pharmaceutical Ltd.
Scope of the Study
Market Segmentation:
By Treatment
By Tests
By Country
Companies Profiled
Unique Offerings from the Publisher
Elements of adult and gender identity can never be realized in infertile individuals due to the loss of pregnancy, childbirth, and lack of family and generational continuity and inclusiveness within their wider community. High levels of clinically relevant symptoms of depression and anxiety, suicidal thoughts, and a heavy conceptualization of grief impact infertile individuals. Mental health and psychosocial problems and resources need to address key factors of depression, such as poverty, sexual abuse, and infertility.
Growing rates of infertility worldwide and the introduction of assisted reproductive technologies (ARTs) are expected to push the demand for male infertility in the coming years. ARTs address a wide variety of infertility therapies that provide remedies for males facing issues such as reduced sperm count, irregular sperm quality, and poor motility. In addition, ARTs deliver a high success rate compared to drugs. The demand for male infertility is expected to see substantial development in the future due to technical developments in the area of assisted reproductive technology.
Increased demand for Assisted Reproductive Technologies [ART] is the most important reason for increasing income for male infertility worldwide. Assisted Reproductive Technologies [ART] assists males suffering from low sperm counts, sperm with reduced motility, or no sperm counts. In addition, a higher percentage of achievements related to medicine and improvement in expertise is expected to raise demand in the immediate future. It stimulates the growth of the market.
Based on Treatment, the market is segmented into Assisted Reproductive Technology & Varicocele Surgery and Medication. Based on Test, the market is segmented into DNA Fragmentation Technique, Oxidative Stress Analysis, Computer Assisted Semen Analysis, Microscopic Examination, Sperm Agglutination, Sperm Penetration Assay and Other Tests. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Sanofi S.A., Bayer AG, Cadila Healthcare Ltd. (Zydus Cadila), Endo International PLC, Aytu BioScience, Inc., Vitrolife AB, SCSA Diagnostics, Inc., Andrology Solutions Limited, Halotech DNA SL, and Intas Pharmaceutical Ltd.
Scope of the Study
Market Segmentation:
By Treatment
- Assisted Reproductive Technology & Varicocele Surgery and
- Medication
By Tests
- DNA Fragmentation Technique
- Oxidative Stress Analysis
- Computer Assisted Semen Analysis
- Microscopic Examination
- Sperm Agglutination
- Sperm Penetration Assay and
- Other Tests
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Companies Profiled
- Sanofi S.A.
- Bayer AG
- Cadila Healthcare Ltd. (Zydus Cadila)
- Endo International PLC
- Aytu BioScience, Inc.
- Vitrolife AB
- SCSA Diagnostics, Inc.
- Andrology Solutions Limited
- Halotech DNA SL
- Intas Pharmaceutical Ltd.
Unique Offerings from the Publisher
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Europe Male Infertility Market by Treatment
Chapter 4. Europe Male Infertility Market by Test
Chapter 5. Europe Male Infertility Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- Sanofi S.A.
- Bayer AG
- Cadila Healthcare Ltd. (Zydus Cadila)
- Endo International PLC
- Aytu BioScience, Inc.
- Vitrolife AB
- SCSA Diagnostics, Inc.
- Andrology Solutions Limited
- Halotech DNA SL
- Intas Pharmaceutical Ltd.
Methodology
LOADING...
